Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are reasonably well and able to carry out daily activities, based on a standard cancer health scale rated 0 to 2 (where 0 means fully active and 2 means limited in physically strenuous activity but able to walk and do light work).
- People with multiple myeloma that has come back or stopped responding to treatment, who have already tried at least two different myeloma treatments — including at least one from each of these three types: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody treatment (where that treatment was available to them).
Who may not be able to join:
- People who have previously received a treatment that targets a protein called BCMA on myeloma cells.
- People who have previously received a type of treatment called CAR-T cell therapy.
- People who have received any anti-cancer treatment within 3 weeks, or within 5 half-lives of that drug (whichever period is shorter), before the first dose of the trial drug CM336.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hongmei Jing, Peking University Third Hospital
Phone: 028-88610620
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicities (DLTs); Adverse events (AEs); Overall Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.